Fosun’s $800m R&D Investment: Evolution Or Revolution?
This article was originally published in PharmAsia News
Executive Summary
Shanghai Fosun Pharmaceutical’s new planned investment in R&D is significant, although it is likely to result in incremental but profitable returns rather than novel blockbuster drugs.